The group developed a decision tool to predict survival outcomes in older AML patients using mutations in seven genes, NPM1, NRAS, KRAS, ASXL1, DNMT3A, TP53, and FLT3-ITD. The gene discussed is TP53; the disease is acute myeloid leukemia.